Harrow has announced an initiative to expand access and affordability for its ophthalmic pharmaceutical products. This includes a program of targeted price reductions for several Harrow products and a ...

LUNA is an ongoing double-masked, randomized Phase 2 trial. OPTIC is an ongoing, open-label, dose-ranging first-in-human ...

ABI-110 has the potential to offer a durable and effective solution by addressing the root causes of wet AMD at the genetic level.

Gregg T. Kokame, MD, MMM, FASRS, is set to share data from a predefined subgroup of the sozinibercept Phase 2b wet AMD trial related to patients with polypoidal choroidal vasculopathy (PCV), measured ...

ARVN001 is indicated for the treatment of uveitic macular edema (UME) and certain other ophthalmic indications under development. Arctic Vision has signed a new commercial collaboration agreement with ...

The European Commission (EC) has approved OPUVIZ 40 mg/mL solution for injection in a vial. OPUVIZ is a biosimilar ...

Previously, under a third of NHS eye care services were offering OCT imaging. There were disparities based on region, as well, according to the NHS news release. Now, all NHS staff are being trained ...

The FDA comments in the CRL relate to proposed labelling language, not safety, Astellas said in a press release.

FYB203 has been recommended by the CHMP for approval in Europe for treating adult patients with age-related neovascular macular degeneration (nAMD) and other serious retinal diseases.